Case Study: Global Hyperhidrosis Service Provider achieves 105% of enrollment goal and lowers screen-failure rates with IQVIA

Global Hyperhidrosis Study Achieves 105% of Enrollment Goal

Global Hyperhidrosis Service Provider engaged IQVIA (IQVIA Biotech) to run a Phase III axillary hyperhidrosis safety and efficacy study across 41 U.S. and 10 German sites. The program faced strict inclusion criteria (gravimetric sweat >50 mg, severity scores), historically high screen-failure rates (~33%), and the need to recruit a large, experienced patient population on a compressed startup and enrollment timeline.

IQVIA lowered screen failures and sped enrollment by selecting experienced hyperhidrosis sites, using a TV/radio-focused recruitment campaign, delivering gravimetric-measurement training (investigator/CRA sessions and a whiteboard video), and optimizing collection techniques (pad type, arm position, timing). The study screened 997 patients (vs. 948 planned) and randomized 697 (105% of the 660-patient goal), randomized 504 subjects by week 22 (53% above target), completed enrollment in 31 weeks (18% faster), and achieved up to a 20% improvement in screen-failure rates — results credited to IQVIA’s strategy.